L D Jacobs

Summary

Affiliation: State University of New York at Buffalo
Country: USA

Publications

  1. ncbi Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
    L D Jacobs
    Department of Neurology, State University of New York School of Medicine at Buffalo and Buffalo General Hospital, 14203, USA
    N Engl J Med 343:898-904. 2000
  2. ncbi Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation, OH 44106, USA
    J Neuroimmunol 93:8-14. 1999
  3. ncbi Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium
    B Weinstock-Guttman
    William C Baird Multiple Sclerosis Research Center, The Jacobs Neurological Institute, Buffalo, NY 14203, USA
    Mult Scler 9:293-8. 2003

Detail Information

Publications3

  1. ncbi Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group
    L D Jacobs
    Department of Neurology, State University of New York School of Medicine at Buffalo and Buffalo General Hospital, 14203, USA
    N Engl J Med 343:898-904. 2000
    ..Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical demyelinating event is of value...
  2. ncbi Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation, OH 44106, USA
    J Neuroimmunol 93:8-14. 1999
    ..The objectives of the current study were to determine: (a) whether CSF abnormalities in MS patients correlated with disease or MRI characteristics, and (b) effects of IFNbeta-1a therapy on these CSF abnormalities...
  3. ncbi Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium
    B Weinstock-Guttman
    William C Baird Multiple Sclerosis Research Center, The Jacobs Neurological Institute, Buffalo, NY 14203, USA
    Mult Scler 9:293-8. 2003
    ..Our findings suggest a racial influence in MS. Further genetic studies that consider race differences are warranted to elucidate mechanisms of disease susceptibility...